Legend Biotech announced strong five-year follow-up data for its CARVYKTI treatment in relapsed/refractory multiple myeloma patients, showing 50% remained progression-free. This positive clinical data suggests the drug's potential for durable remission and earlier-line use, which could significantly expand its market and revenue potential.
Legend Biotech reported highly positive five-year follow-up data for CARVYKTI in multiple myeloma, with 50% of patients remaining progression-free and an overall survival rate of 69.2%. This data, presented at a major medical conference, strengthens the case for CARVYKTI's efficacy and potential for earlier-line use, which could significantly expand its addressable market. For traders, this represents a strong positive catalyst for LEGN, as it de-risks the drug's long-term prospects and revenue generation. The long-term implications are a potential shift in multiple myeloma treatment paradigms, benefiting Legend Biotech and its partner, Johnson & Johnson (JNJ), while potentially posing a competitive threat to other myeloma treatments.